A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience
Background/AimsThe widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue.Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma, recent reports have suggested that rituximab therapy increases the risk of viral-med